These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22990083)

  • 21. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5.
    Pitman R; Fisman D; Zaric GS; Postma M; Kretzschmar M; Edmunds J; Brisson M;
    Med Decis Making; 2012; 32(5):712-21. PubMed ID: 22990086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The view of a model user on the ISPOR-SMDM modeling good research task force report.
    Berger ML
    Value Health; 2012; 15(6):794-5. PubMed ID: 22999127
    [No Abstract]   [Full Text] [Related]  

  • 26. A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework.
    Kunst N; Burger EA; Coupé VMH; Kuntz KM; Aas E
    Pharmacoeconomics; 2024 Apr; 42(4):363-371. PubMed ID: 38157129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.
    Vemer P; van Voom GA; Ramos IC; Krabbe PF; Al MJ; Feenstra TL
    Value Health; 2013; 16(6):1106-7. PubMed ID: 24041364
    [No Abstract]   [Full Text] [Related]  

  • 28. Reporting Quality of Discrete Event Simulations in Healthcare-Results From a Generic Reporting Checklist.
    Zhang X; Lhachimi SK; Rogowski WH
    Value Health; 2020 Apr; 23(4):506-514. PubMed ID: 32327168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.
    Thokala P; Devlin N; Marsh K; Baltussen R; Boysen M; Kalo Z; Longrenn T; Mussen F; Peacock S; Watkins J; Ijzerman M
    Value Health; 2016 Jan; 19(1):1-13. PubMed ID: 26797229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.
    Pitman R; Fisman D; Zaric GS; Postma M; Kretzschmar M; Edmunds J; Brisson M;
    Value Health; 2012; 15(6):828-34. PubMed ID: 22999132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.
    Reed Johnson F; Lancsar E; Marshall D; Kilambi V; Mühlbacher A; Regier DA; Bresnahan BW; Kanninen B; Bridges JF
    Value Health; 2013; 16(1):3-13. PubMed ID: 23337210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Osgood ND; Padula WV; Higashi MK; Wong PK; Pasupathy KS; Crown W
    Value Health; 2015 Jan; 18(1):5-16. PubMed ID: 25595229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
    Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
    Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.